Do Wegovy and Ozempic Have the Same Side Effects?
Wegovy (semaglutide 2.4 mg weekly) and Ozempic (semaglutide 0.5-2 mg weekly) share the same active ingredient, so their side effect profiles overlap significantly. Both cause gastrointestinal issues like nausea, vomiting, diarrhea, constipation, and abdominal pain, which affect 20-44% of users depending on the symptom.[1][2] These occur because semaglutide slows gastric emptying and acts on GLP-1 receptors in the gut. Serious risks like pancreatitis, gallbladder disease, kidney issues, and thyroid tumors (from rodent studies) appear identical across labels.[1][2]
Why Might Side Effects Differ Between Them?
Differences arise mainly from dosing and patient factors, not the drug itself. Wegovy starts at 0.25 mg and titrates to 2.4 mg over 16 weeks for weight loss, while Ozempic maxes at 2 mg for diabetes over 4-8 weeks. Higher Wegovy doses lead to more frequent or intense GI effects during ramp-up—nausea hits 44% on 2.4 mg vs. 20% on Ozempic's 2 mg.[1][3] Discontinuation due to side effects is 7% for Wegovy vs. 4% for Ozempic in trials.[1][2]
| Side Effect | Ozempic (up to 2 mg) Frequency | Wegovy (2.4 mg) Frequency |
|-------------|-------------------------------|---------------------------|
| Nausea | 15-20% [2] | 44% [1] |
| Diarrhea | 8-10% [2] | 30% [1] |
| Vomiting | 5-9% [2] | 24% [1] |
| Constipation | 3-5% [2] | 24% [1] |
Real-world reports note Wegovy users experience more "Ozempic face" (facial fat loss from rapid weight reduction), but this stems from 15% average body weight loss on Wegovy vs. 1 kg on Ozempic, not a unique drug effect.[3][4]
Are There Truly Unique Side Effects?
No side effects are exclusive to one drug per FDA labels or trials—both carry identical black-box warnings for thyroid C-cell tumors.[1][2] Minor variances show in post-marketing data: Wegovy has more reports of hair loss or muscle loss tied to faster weight reduction, but these aren't labeled as distinct.[4] Hypoglycemia risk is low for both unless combined with insulin/sulfonylureas.[1][2]
What Do Patients Report in Practice?
Forum and app data (e.g., Reddit, Drugs.com) highlight Wegovy's tougher GI startup due to higher endpoint dose, with some switching from Ozempic citing better tolerability on lower doses. Injection-site reactions are comparable at 0.6-1.4%.[1][2] Long-term, both risk bowel obstruction or gastroparesis, with 2024 lawsuits targeting semaglutide generally.[5]
How to Manage Side Effects on Either
Start low, go slow with titration; eat smaller meals, stay hydrated. If issues persist, providers often drop dose or switch products. Both require monitoring for dehydration from vomiting/diarrhea.[1][2]
[1]: FDA Wegovy Label
[2]: FDA Ozempic Label
[3]: NEJM STEP Trials (Wegovy), Lancet SUSTAIN Trials (Ozempic)
[4]: Drugs.com User Reviews
[5]: Novo Nordisk Safety Updates